Interventional Oncology Market by Product (Radiofrequency, microwave, embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), Enduser (Hospital, ASC) - Global Industry Analysis, Share ,Growth ,Regional Outlook And Forecasts, 2021-2027

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Interventional Oncology Market, By Product

7.1.  Interventional Oncology  Market, By Product, 2020-2027

7.1.1.     Embolization Devices

7.1.1.1.          Market Revenue and Forecast (2016-2027)

7.1.2.     Ablation Devices

7.1.2.1.          Market Revenue and Forecast (2016-2027)

7.1.3.     Support Devices

7.1.3.1.          Market Revenue and Forecast (2016-2027)

Chapter 8.    Global Interventional Oncology Market, By Procedure

8.1.  Interventional Oncology  Market, By Procedure, 2020-2027

8.1.1.     Thermal Tumor Ablation

8.1.1.1.          Market Revenue and Forecast (2016-2027)

8.1.2.     Non-Thermal Tumor Ablation

8.1.2.1.          Market Revenue and Forecast (2016-2027)

8.1.3.     Transcatheter Arterial Chemoembolization

8.1.3.1.          Market Revenue and Forecast (2016-2027)

8.1.4.     Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy

8.1.4.1.          Market Revenue and Forecast (2016-2027)

8.1.5.     Transcatheter Arterial Embolization/Bland Embolization

8.1.5.1.          Market Revenue and Forecast (2016-2027)

Chapter 9.    Global Interventional Oncology Market, By Cancer Type

9.1.  Interventional Oncology  Market, By Cancer Type, 2020-2027

9.1.1.     Liver Cancer

9.1.1.1.          Market Revenue and Forecast (2016-2027)

9.1.2.     Lung Cancer

9.1.2.1.          Market Revenue and Forecast (2016-2027)

9.1.3.     Bone Metastasis

9.1.3.1.          Market Revenue and Forecast (2016-2027)

9.1.4.     Kidney Cancer

9.1.4.1.          Market Revenue and Forecast (2016-2027)

9.1.5.     Breast Cancer

9.1.5.1.          Market Revenue and Forecast (2016-2027)

9.1.6.     Breast Cancer

9.1.6.1.          Market Revenue and Forecast (2016-2027)

9.1.7.     Other Cancers

9.1.7.1.          Market Revenue and Forecast (2016-2027)

Chapter 10.Global Interventional Oncology Market, By End Users

10.1.          Interventional Oncology  Market, By End Users, 2020-2027

10.1.1.  Hospitals

10.1.1.1.       Market Revenue and Forecast (2016-2027)

10.1.2.  Ambulatory Surgery Centers

10.1.2.1.       Market Revenue and Forecast (2016-2027)

10.1.3.  Research & Academic Institutes

10.1.3.1.       Market Revenue and Forecast (2016-2027)

Chapter 11.Global Interventional Oncology  Market, Regional Estimates and Trend Forecast

11.1.          North America

11.1.1.  Market Revenue and Forecast, By Product (2016-2027)

11.1.2.  Market Revenue and Forecast, By Procedure (2016-2027)

11.1.3.  Market Revenue and Forecast, By Cancer Type (2016-2027)

11.1.4.  Market Revenue and Forecast, By End Users (2016-2027)

11.1.5.  U.S.

11.1.5.1.       Market Revenue and Forecast, By Product (2016-2027)

11.1.5.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.1.5.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.1.5.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.1.6.  Rest of North America

11.1.6.1.       Market Revenue and Forecast, By Product (2016-2027)

11.1.6.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.1.6.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.1.6.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.2.          Europe

11.2.1.  Market Revenue and Forecast, By Product (2016-2027)

11.2.2.  Market Revenue and Forecast, By Procedure (2016-2027)

11.2.3.  Market Revenue and Forecast, By Cancer Type (2016-2027)

11.2.4.  Market Revenue and Forecast, By End Users (2016-2027)

11.2.5.  UK

11.2.5.1.       Market Revenue and Forecast, By Product (2016-2027)

11.2.5.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.2.5.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.2.5.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.2.6.  Germany

11.2.6.1.       Market Revenue and Forecast, By Product(2016-2027)

11.2.6.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.2.6.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.2.6.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.2.7.  France

11.2.7.1.       Market Revenue and Forecast, By Product (2016-2027)

11.2.7.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.2.7.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.2.7.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.2.8.  Rest of Europe

11.2.8.1.       Market Revenue and Forecast, By Product (2016-2027)

11.2.8.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.2.8.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.2.8.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.3.          APAC

11.3.1.  Market Revenue and Forecast, By Product (2016-2027)

11.3.2.  Market Revenue and Forecast, By Procedure (2016-2027)

11.3.3.  Market Revenue and Forecast, By Cancer Type (2016-2027)

11.3.4.  Market Revenue and Forecast, By End Users (2016-2027)

11.3.5.  India

11.3.5.1.       Market Revenue and Forecast, By Product (2016-2027)

11.3.5.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.3.5.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.3.5.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.3.6.  China

11.3.6.1.       Market Revenue and Forecast, By Product (2016-2027)

11.3.6.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.3.6.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.3.6.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.3.7.  Japan

11.3.7.1.       Market Revenue and Forecast, By Product (2016-2027)

11.3.7.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.3.7.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.3.7.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.3.8.  Rest of APAC

11.3.8.1.       Market Revenue and Forecast, By Product (2016-2027)

11.3.8.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.3.8.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.3.8.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.4.          MEA

11.4.1.  Market Revenue and Forecast, By Product (2016-2027)

11.4.2.  Market Revenue and Forecast, By Procedure (2016-2027)

11.4.3.  Market Revenue and Forecast, By Cancer Type (2016-2027)

11.4.4.  Market Revenue and Forecast, By End Users (2016-2027)

11.4.5.  GCC

11.4.5.1.       Market Revenue and Forecast, By Product (2016-2027)

11.4.5.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.4.5.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.4.5.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.4.6.  North Africa

11.4.6.1.       Market Revenue and Forecast, By Product (2016-2027)

11.4.6.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.4.6.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.4.6.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.4.7.  South Africa

11.4.7.1.       Market Revenue and Forecast, By Product (2016-2027)

11.4.7.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.4.7.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.4.7.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.4.8.  Rest of MEA

11.4.8.1.       Market Revenue and Forecast, By Product (2016-2027)

11.4.8.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.4.8.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.4.8.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.5.          Latin America

11.5.1.  Market Revenue and Forecast, By Product (2016-2027)

11.5.2.  Market Revenue and Forecast, By Procedure (2016-2027)

11.5.3.  Market Revenue and Forecast, By Cancer Type (2016-2027)

11.5.4.  Market Revenue and Forecast, By End Users (2016-2027)

11.5.5.  Brazil

11.5.5.1.       Market Revenue and Forecast, By Product (2016-2027)

11.5.5.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.5.5.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.5.5.4.       Market Revenue and Forecast, By End Users (2016-2027)

11.5.6.  Rest of LATAM

11.5.6.1.       Market Revenue and Forecast, By Product (2016-2027)

11.5.6.2.       Market Revenue and Forecast, By Procedure (2016-2027)

11.5.6.3.       Market Revenue and Forecast, By Cancer Type (2016-2027)

11.5.6.4.       Market Revenue and Forecast, By End Users (2016-2027)

Chapter 12.   Company Profiles

12.1.                 Medtronic (Ireland)

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.                 Boston Scientific (US)

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.                 BD (US)

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.                 Terumo (Japan)

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.                 Merit Medical (US)

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.                 AngioDynamics (US)

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.                 J&J (US)

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.                 Teleflex (US)

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.                 Cook Medical (US)

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.              HealthTronics (US)

12.10.1.                   Company Overview

12.10.2.                   Product Offerings

12.10.3.                   Financial Performance

12.10.4.                   Recent Initiatives

12.11.              MedWaves (US), Sanarus (US)

12.11.1.                   Company Overview

12.11.2.                   Product Offerings

12.11.3.                   Financial Performance

12.11.4.                   Recent Initiatives

12.12.              Trod Medical (US)

12.12.1.                   Company Overview

12.12.2.                   Product Offerings

12.12.3.                   Financial Performance

12.12.4.                   Recent Initiatives

12.13.              IceCure Medical (Israel)

12.13.1.                   Company Overview

12.13.2.                   Product Offerings

12.13.3.                   Financial Performance

12.13.4.                   Recent Initiatives

12.14.              Mermaid Medicals (Denmark)

12.14.1.                   Company Overview

12.14.2.                   Product Offerings

12.14.3.                   Financial Performance

12.14.4.                   Recent Initiatives

12.15.              Interface Biomaterials BV (Netherlands)

12.15.1.                   Company Overview

12.15.2.                   Product Offerings

12.15.3.                   Financial Performance

12.15.4.                   Recent Initiatives

12.16.              Guerbet (France)

12.16.1.                   Company Overview

12.16.2.                   Product Offerings

12.16.3.                   Financial Performance

12.16.4.                   Recent Initiatives

12.17.              ABK Biomedical (Canada)

12.17.1.                   Company Overview

12.17.2.                   Product Offerings

12.17.3.                   Financial Performance

12.17.4.                   Recent Initiatives

12.18.              Shape Memory Medical (US)

12.18.1.                   Company Overview

12.18.2.                   Product Offerings

12.18.3.                   Financial Performance

12.18.4.                   Recent Initiatives

12.19.              Endo Shape (US)

12.19.1.                   Company Overview

12.19.2.                   Product Offerings

12.19.3.                   Financial Performance

12.19.4.                   Recent Initiatives

12.20.              Monteris Medical (US)

12.20.1.                   Company Overview

12.20.2.                   Product Offerings

12.20.3.                   Financial Performance

12.20.4.                   Recent Initiatives

12.21.              Instylla (US)

12.21.1.                   Company Overview

12.21.2.                   Product Offerings

12.21.3.                   Financial Performance

12.21.4.                   Recent Initiatives

12.22.              Trisalus Lifesciences (US)

12.22.1.                   Company Overview

12.22.2.                   Product Offerings

12.22.3.                   Financial Performance

12.22.4.                   Recent Initiatives

12.23.              Profound Medical Corp (Canada)

12.23.1.                   Company Overview

12.23.2.                   Product Offerings

12.23.3.                   Financial Performance

12.23.4.                   Recent Initiatives

12.24.              Sirtex (US)

12.24.1.                   Company Overview

12.24.2.                   Product Offerings

12.24.3.                   Financial Performance

12.24.4.                   Recent Initiatives

12.25.              Accuray (US)

12.25.1.                   Company Overview

12.25.2.                   Product Offerings

12.25.3.                   Financial Performance

12.25.4.                   Recent Initiatives

12.26.              Baylis Medical (Canada)

12.26.1.                   Company Overview

12.26.2.                   Product Offerings

12.26.3.                   Financial Performance

12.26.4.                   Recent Initiatives

12.27.              ALPINION MEDICAL SYSTEMS (South Korea)

12.27.1.                   Company Overview

12.27.2.                   Product Offerings

12.27.3.                   Financial Performance

12.27.4.                   Recent Initiatives

Chapter 13.   Research Methodology

13.1.                 Primary Research

13.2.                 Secondary Research

13.3.                 Assumptions

Chapter 14.   Appendix

14.1.                 About Us

14.2.                 Glossary of Terms